Chairperson:
Robert A Figlin, MD, FACP City of Hope National Medical Center Duarte, California
Faculty:
Robert Dreicer, MD Cleveland Clinic Cleveland, Ohio	A Oliver Sartor, MD Tulane University New Orleans, Louisiana		Matthew R Smith, MD, PhD Massachusetts General Hospital Boston, Massachusetts
Content Reviewer:
Thomas Gardner, MD Indiana University School of Medicine Department of Urology Indianapolis, Indiana

6.00 PM	Registration and reception
6.30 PM	Welcome and introduction Robert A Figlin, MD, FACP
6.35 PM	Advanced prostate cancer: Implications and management of bone metastases Matthew R Smith, MD, PhD
6.55 PM	The evolving role of chemotherapy in castration-resistant prostate cancer A Oliver Sartor, MD
7.15 PM	Prognostic and predictive biomarkers in renal cell carcinoma (RCC): Implications for therapeutic decision making Robert Dreicer, MD
7.35 PM	Selecting and sequencing targeted therapy in metastatic RCC Robert A Figlin, MD, FACP
7.55 PM	Concluding remarks Robert A Figlin, MD, FACP

This educational activity has been developed to provide medical oncologists, radiation oncologists, surgeons, urologists, and other healthcare professionals with a comprehensive overview of recent advances in the management of prostate and renal cell cancers.

Recent clinical studies have provided data supporting new strategies for the management of prostate cancer and renal cell carcinoma. Integration of new information and novel regimens into clinical practice is both challenging and necessary. As new information becomes available, it is essential that healthcare providers and researchers are kept abreast of advances in these fields. Improving Outcomes in Prostate and Renal Cell Carcinomas will discuss emerging data and provide updates that are relevant to clinicians who provide care to patients with prostate cancer and renal cell carcinoma.

At the conclusion of this activity, participants should be able to:
    

• List therapeutic approaches to optimize outcomes for patients with advanced prostate cancer, including the importance of managing bone metastases
• Compare and contrast traditional chemotherapies with novel chemotherapeutic agents in the management of patients with castration-resistant prostate cancer
• Discuss the rationale and evaluate the clinical utility of biomarkers to guide the therapeutic decision-making process in patients with renal cell carcinoma
• Describe current management strategies utilizing targeted therapies for patients with metastatic renal cell carcinoma based on prognostic risk stratification and toxicity-related issues

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of IUSM and prIME Oncology. IUSM is accredited by the ACCME to provide continuing medical education for physicians.

In accordance with the ACCME Standards for Commercial Support, educational programs sponsored by IUSM must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in an IUSM-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.